Targeted Antigens of CAR-T Cell Therapy Information
| Target General Information | |||||
|---|---|---|---|---|---|
| Target ID | T13017 | Target Info | |||
| Target Name | Syndecan-1 (SDC1) | ||||
| Synonyms | SYND1; SDC; CD138 | ||||
| Target Type | Clinical trial Target | ||||
| Gene Name | SDC1 | ||||
| Biochemical Class | Peptide translocating syndecan | ||||
| UniProt ID | |||||
| Targeted Antigens of CAR-T Cell Therapy | |||||
| CAR T-Cell Therapy Drug(s) | CART-138 cells | Drug Info | Phase 1/2 | Multiple myeloma | [1] |
| CART-138 cells | Drug Info | Phase 1/2 | Multiple myeloma | [2] | |
| CD138 CAR T cells | Drug Info | Phase 1/2 | Multiple myeloma | [3] | |
| CAR138 T Cells | Drug Info | Phase 1 | Multiple myeloma | [4] | |
| CAR-T cells targeting CD138 | Drug Info | Clinical trial | Multiple myeloma | [5] | |
| References | |||||
| REF 1 | ClinicalTrials.gov (NCT01886976) Treatment of Chemotherapy Refractory Multiple Myeloma by CART-138 | ||||
| REF 2 | ClinicalTrials.gov (NCT03196414) Study of CART-138/BCMA Therapy for R/R Multiple Myeloma | ||||
| REF 3 | ClinicalTrials.gov (NCT03271632) Multi-CAR T Cell Therapy in the Treatment of Multiple Myeloma | ||||
| REF 4 | ClinicalTrials.gov (NCT03672318) Study of ATLCAR.CD138 Cells for Relapsed/Refractory Multiple Myeloma | ||||
| REF 5 | ClinicalTrials.gov (NCT03473496) CAR-T Cells Therapy in Relapsed/Refractory Multiple Myeloma | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Wang and Dr. Li.